Spoken Alpha
Ernexa Therapeutics Inc.
Ernexa Therapeutics develops synthetic allogeneic induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) for cell therapy treatments. The company's lead candidate, ERNA-101, is designed to deliver immune-activating cytokines directly to tumors to treat platinum-resistant ovarian cancer, with a Phase I trial expected in late 2026.
Ernexa Therapeutics Inc is a Healthcare company operating in Biotechnology with a $5.0M market cap.
ERNA missed consensus EPS by 0.0% in Q2 FY2026, reported Aug 11, 2026.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-08-30.
Transcripts
We index calls for roughly 3,000 US-listed companies. If you'd like us to add ERNA, reply to your welcome email and we'll prioritize it.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ERNA.
$ curl https://api.spokenalpha.com/v1/companies/ERNAFAQ
Spoken Alpha indexes ERNA's earnings call transcripts at https://spokenalpha.com/companies/ERNA. Each call links to attributed speakers and parsed analyst Q&A. Ernexa Therapeutics Inc.'s own investor relations page is at https://investor.ernexatx.com/.
Ernexa Therapeutics Inc. (ERNA) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | $-3.40 | $-3.30 | -3.0% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $-6.95 | $-1.95 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-23 | $-4.81 | — | — | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-06 | $-0.15 | $0.00 | — | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-12 | $-0.61 | $0.00 | — | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $-2.31 | $0.00 | — | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-11 | $-0.15 | $0.00 | — | $1.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-28 | $-1844.09 | — | — | $487.0K | — | — | EODHD |
| Q2 FY2024 | 2024-08-11 | $-383.80 | — | — | $47.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-21 | $-460.74 | — | — | $47.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-18 | $-427.06 | — | — | $17.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-1.03 | — | — | $51.0K | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-0.85 | — | — | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-10 | $-1.24 | $-0.14 | -100.0% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-19 | $-1.24 | $-0.14 | -100.0% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-933.75 | $-825.00 | -13.2% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-450.00 | $-975.00 | +53.8% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-04-14 | $-3.20 | $-937.50 | +99.7% | $0 | — | — | EODHD |
| Q4 FY2021 | 2021-12-30 | $-3.20 | $-937.50 | +99.7% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-11 | $-12749.99 | $-600.00 | -100.0% | $0 | — | — | EODHD |
Source: EODHD. ERNA reported actuals as published; sparse fields render as —.